Traumakine7 Dec 2019 07:53
FDA update next week
News on this!
"The Company is exploring various options for future API manufacturing. This termination has no impact on the currently on-going clinical advice process with FDA/EMA, which focuses on the structure of the next Traumakine clinical study"
And then this:
"The Company will have a face-to-face meeting with the FDA in early December 2019, which is expected to result in a written opinion of the FDA on the Company's clinical development plan for Traumakine"
And this:
"The Company currently envisages that a further Traumakine trial is likely to be funded through third party funding"